Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 10;22(18):9815.
doi: 10.3390/ijms22189815.

Pharmacogenetics in Neuroblastoma: What Can Already Be Clinically Implemented and What Is Coming Next?

Gladys G Olivera  1   2 , Andrea Urtasun  3   4 , Luis Sendra  1   2 , Salvador F Aliño  1   2 , Yania Yáñez  3 , Vanessa Segura  3 , Pablo Gargallo  3 , Pablo Berlanga  5 , Victoria Castel  3 , Adela Cañete  3 , María José Herrero  1   2
Affiliations
Review

Pharmacogenetics in Neuroblastoma: What Can Already Be Clinically Implemented and What Is Coming Next?

Gladys G Olivera et al. Int J Mol Sci. .

Abstract

Pharmacogenetics is one of the cornerstones of Personalized Precision Medicine that needs to be implemented in the routine of our patients' clinical management in order to tailor their therapies as much as possible, with the aim of maximizing efficacy and minimizing toxicity. This is of great importance, especially in pediatric cancer and even more in complex malignancies such as neuroblastoma, where the rates of therapeutic success are still below those of many other types of tumors. The studies are mainly focused on germline genetic variants and in the present review, state of the art is presented: which are the variants that have a level of evidence high enough to be implemented in the clinic, and how to distinguish them from the ones that still need validation to confirm their utility. Further aspects as relevant characteristics regarding ontogeny and future directions in the research will also be discussed.

Keywords: SNP (single nucleotide polymorphism); chemotherapy; clinical implementation guidelines; drug label.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Tolbert V.P., Coggins G.E., Maris J.M. Genetic susceptibility to neuroblastoma. Curr. Opin. Genet. Dev. 2017;42:81–90. doi: 10.1016/j.gde.2017.03.008. - DOI - PMC - PubMed
    1. Hero B., Simon T., Spitz R., Ernestus K., Gnekow A.K., Scheel-Walter H.G., Schwabe D., Schilling F.H., Benz-Bohm G., Berthold F. Localized infant neuroblastomas often show spontaneous regression: Results of the prospective trials NB95-S and NB97. J. Clin. Oncol. 2008;26:1504–1510. doi: 10.1200/JCO.2007.12.3349. - DOI - PubMed
    1. Park J.R., Bagatell R., Cohn S.L., Pearson A.D., Villablanca J.G., Berthold F., Burchill S., Boubaker A., McHugh K., Nuchtern J.G., et al. Revisions to the international neuroblastoma response criteria: A consensus statement from the National Cancer Institute clinical trials planning meeting. J. Clin. Oncol. 2017;35:2580–2587. doi: 10.1200/JCO.2016.72.0177. - DOI - PMC - PubMed
    1. Morgenstern D.A., Pötschger U., Moreno L., Papadakis V., Owens C., Ash S., Pasqualini C., Luksch R., Garaventa A., Canete A., et al. Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN study. Pediatr. Blood Cancer. 2018;65:e27363. doi: 10.1002/pbc.27363. - DOI - PubMed
    1. Clemens E., van der Kooi A.L.F., Broer L., van Dulmen-den Broeder E., Visscher H., Kremer L., Tissing W., Loonen J., Ronckers C.M., Pluijm S.M.F., et al. The influence of genetic variation on late toxicities in childhood cancer survivors: A review. Crit. Rev. Oncol. Hematol. 2018;126:154–167. doi: 10.1016/j.critrevonc.2018.04.001. - DOI - PubMed

MeSH terms

Substances